Moderna, Inc. (MRNA)

Nasdaq · Cambridge, Massachusetts, USA · Founded 2010 · CEO Stéphane Bancel

Valuation summary

Fair value is not meaningful for this company — the model produces a negative equity value. Rated Sell.

Fair value per shareN/M
Current share price$199.33
Upside / downside-102.1%
Bear caseN/M
Bull caseN/M
Discount rate (WACC)13.9%
Terminal growth3.00%
Market capitalisation$80B
EV / Sales35.0x

About Moderna, Inc.

Founded in 2010 to develop messenger RNA therapeutics, an approach with no approved products until COVID-19 vaccines validated it at extraordinary speed. Stéphane Bancel has been CEO since 2011. Revenue collapsed from pandemic peaks and Moderna is now spending heavily to prove mRNA works beyond COVID — in RSV, influenza, and most importantly individualised cancer vaccines.

Investment case

  • The mRNA platform allows far faster development cycles than conventional biologics.
  • Individualised neoantigen therapy intismeran, with Merck's Keytruda, met its primary recurrence-free survival endpoint in the Phase 3 INTerpath-001 melanoma trial in August 2026.
  • Cash plus $2.6 billion of convertible notes raised in August 2026 funds oncology expansion and several more years of development.

Key risks

  • Deeply lossmaking, with revenue far below the cost base built during the pandemic.
  • COVID vaccine demand continues to decline and is now seasonal at best.
  • After the August 2026 melanoma readout the valuation assumes regulatory approval and commercial success for cancer vaccines that have not yet been filed.

Recent developments

Revenue by segment

COVID-19 Vaccines62%
RSV & Flu20%
Other & Collaborations18%

Five-year forecast

RevenueFree cash flow
Year 1$2.6B$-0.7B
Year 2$3.0B$-0.5B
Year 3$3.3B$-0.3B
Year 4$3.6B$-0.0B
Year 5$4.0B$0.3B

What the street says

The August 2026 Phase 3 melanoma success has turned the debate from whether the cancer platform works to how large it can become, and the shares traded around $143 by late August. Moderna joins the Nasdaq-100 on 9 October 2026. Bears still point to a heavily lossmaking respiratory business and the dilution embedded in the new convertible.

Comparable companies: CAH · MCK · COR · HUM · DXCM · MDLN · CNC · INSM

Open the interactive model, price chart and sensitivity grid →